Citadel Advisors
KRTX

Citadel Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Citadel Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-47,000
Closed -$14.9M – 15739
2023
Q4 		$14.9M Hold
47,000
– – ﹤0.01% 2351
2023
Q3 		$7.95M Buy
47,000
+2,200
+5% +$414K ﹤0.01% 2974
2023
Q2 		$9.71M Sell
44,800
-14,700
-25% -$3.15M ﹤0.01% 2716
2023
Q1 		$10.8M Buy
59,500
+22,500
+61% +$4.3M ﹤0.01% 2708
2022
Q4 		$7.27M Sell
37,000
-47,500
-56% -$10.2M ﹤0.01% 3269
2022
Q3 		$19M Sell
84,500
-400
-0.5% -$81K ﹤0.01% 1925
2022
Q2 		$10.7M Buy
84,900
+50,900
+150% +$5.85M ﹤0.01% 2593
2022
Q1 		$4.31M Buy
34,000
+25,000
+278% +$2.81M ﹤0.01% 4466
2021
Q4 		$1.18M Buy
9,000
+900
+11% +$116K ﹤0.01% 7545
2021
Q3 		$991K Buy
8,100
+3,000
+59% +$346K ﹤0.01% 8173
2021
Q2 		$581K Sell
5,100
-2,900
-36% -$339K ﹤0.01% 9714
2021
Q1 		$962K Sell
8,000
-3,900
-33% -$442K ﹤0.01% 8218
2020
Q4 		$1.21M Buy
11,900
+4,000
+51% +$371K ﹤0.01% 6395
2020
Q3 		$611K Buy
7,900
+500
+7% +$42.6K ﹤0.01% 6934
2020
Q2 		$825K Buy
7,400
+3,500
+90% +$304K ﹤0.01% 6186
2020
Q1 		$281K Buy
+3,900
New +$334K ﹤0.01% 7456

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Citadel Advisors's KRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 158,012 shares — an estimated $50M sold.

Citadel Advisors first reported a position in KRTX in Q2 2019 and held it in 17 quarters. The position peaked at $50M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Citadel Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 158,012 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $50M.
  • Citadel Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
  • Citadel Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $50M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.